Mankind Pharma PAT up 52 percent at Rs 294 crore in Q4
New Delhi: Mankind Pharma has reported 52 percent increase in consolidated profit after tax (PAT) at Rs 294 crore for March quarter 2022-23, aided by robust sales.
The company had logged a PAT of Rs 193 crore in January-March 2021-22.
Revenue from operations rose to Rs 2,053 crore from Rs 1,726 crore in the year-ago period, Mankind Pharma said in a statement.
In 2022-23, the PAT declined 10 per cent to Rs 1,310 crore from Rs 1,453 crore in the previous year.
"The company maintained its strong growth trajectory during the year..our consumer healthcare business has maintained its double-digit growth with dominant brand leadership in its categories," Mankind Pharma Vice Chairman and Managing Director Rajeev Juneja said.
Earlier this month, the Income Tax Department conducted raids on the premises of the company over allegations of tax evasion.
Read also: Mankind Pharma sets IPO price band of Rs 1,026 to Rs 1,080 per share
Headquartered in Delhi, Mankind Pharma was founded in 1991 by R.C. Juneja. The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
Read also: Mankind Pharma invests in Actimed Therapeutics for cancer cachexia treatment
